CN110876755A - 一种有效缓解干眼症的眼药水 - Google Patents
一种有效缓解干眼症的眼药水 Download PDFInfo
- Publication number
- CN110876755A CN110876755A CN201811034727.6A CN201811034727A CN110876755A CN 110876755 A CN110876755 A CN 110876755A CN 201811034727 A CN201811034727 A CN 201811034727A CN 110876755 A CN110876755 A CN 110876755A
- Authority
- CN
- China
- Prior art keywords
- dry eye
- ophthalmic solution
- solution effective
- xerophthalmia
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种有效缓解干眼症的眼药水,100ml无菌蒸馏水中包括色甘酸钠1000mg,抗组胺15mg,薄荷醇6mg,硼砂10mg,硼酸1800mg,糖胺聚糖15mg。本发明通过在溶液中添加薄荷醇减少由色甘酸钠导致的刺激感,并配合糖胺聚糖治疗干眼症,避免以往眼药水刺激,缺乏治疗干眼症疗效的麻烦。
Description
技术领域
本发明属于眼药水技术领域,具体地说,涉及一种有效缓解干眼症的眼药水。
背景技术
干眼症,又称角结膜干燥或泪液功能不全综合征,是指泪液质和量异常或动力学异常导致的泪膜稳定性下降,并伴有眼部不适,导致眼表组织病变为特征的疾病总称,是目前最常见的眼科疾病之一。该病以中老年人多见,并严重影响患者的生活质量。随着人类生活节奏的加快,气候干燥、空气污染、人口老龄化等问题日益严重,高科技产品的普及和隐形眼镜的广泛应用,干眼症的发病率在眼科门诊的患病人群中逐年上升,并有逐渐年轻化的趋势。
目前,市面上的眼药水大多添杂各种防腐剂或者添加剂,对于眼部刺激较大,而且疗效不够,只能短暂的放松眼部,持久性较差。
发明内容
有鉴于此,本发明所要解决的技术问题是提供了一种有效缓解干眼症的眼药水,通过在溶液中添加薄荷醇减少由色甘酸钠导致的刺激感,并配合糖胺聚糖治疗干眼症,避免以往眼药水刺激,缺乏治疗干眼症疗效的麻烦。
为了解决上述技术问题,本发明公开了一种有效缓解干眼症的眼药水,100ml无菌蒸馏水中包括色甘酸钠1000mg,抗组胺15mg,薄荷醇6mg,硼砂10mg,硼酸1800mg,糖胺聚糖15mg。
根据本发明一实施方式,其中上述糖胺聚糖选自透明质酸。
根据本发明一实施方式,其中上述抗组胺选自马来酸氯苯那敏或盐酸苯海拉明。
根据本发明一实施方式,还包括5~10mg的双氯芬酸的药学活性剂。
根据本发明一实施方式,还包括增粘剂和pH调节剂。
根据本发明一实施方式,其中上述增粘剂选自甲基纤维素,羟乙基纤维素,羧甲基纤维素,羟丙基甲基纤维素,聚乙烯醇。
根据本发明一实施方式,其中上述pH调节剂选自氢氧化钠,氢氧化钾,碳酸钠,柠檬酸,磷酸,乙酸和盐酸。
根据本发明一实施方式,其中上述溶液的pH为7。
与现有技术相比,本发明可以获得包括以下技术效果:
通过在溶液中添加薄荷醇减少由色甘酸钠导致的刺激感,并配合糖胺聚糖治疗干眼症,避免以往眼药水刺激,缺乏治疗干眼症疗效的麻烦。
当然,实施本发明的任一产品必不一定需要同时达到以上所述的所有技术效果。
具体实施方式
以下将配实施例来详细说明本发明的实施方式,藉此对本发明如何应用技术手段来解决技术问题并达成技术功效的实现过程能充分理解并据以实施。
本发明公开了一种有效缓解干眼症的眼药水,通过常规方法蒸馏杀菌制取,其中100ml无菌蒸馏水中包括色甘酸钠1000mg,抗组胺15mg,薄荷醇6mg,硼砂10mg,硼酸1800mg,糖胺聚糖15mg。
在本发明一实施方式中,色甘酸钠别称色甘酸二钠,对速发型过敏反应有着良好的预防与治疗作用,混合入眼药水,能够有效治疗眼部炎症。抗组胺药选自马来酸氯苯那敏或盐酸苯海拉明,与组胺竞争效应细胞上的H1受体,拮抗组胺的作用,可抑制血管渗出、减轻组织水肿,此为其最主要的药理作用,对某些以组织水肿为特征的变态反应疗效好,能够帮助治疗眼部的水肿。而薄荷醇具有较强的止痒作用,可以在滴注后立即抑制眼睛的严重瘙痒,从而防止由患者刮擦引起的眼粘膜眼炎的恶化;还可以减少由色甘酸钠眼科制剂给予的令人不快的刺激性眼痛。此外,薄荷醇的清新和凉爽性质改善了患者在使用该制剂时的感觉并迅速消除了各种令人不愉快的眼睛过敏症状,起到舒缓放松的效果。
糖胺聚糖选自透明质酸,具有润滑的药理效应,起到类似于润滑剂的效果,对于干眼症患者具有抑制泪膜撕裂的作用。此外,硼酸和硼砂作为缓冲剂,提升制配效果。
在本发明优选的实施例中,1000mg的色甘酸钠,15mg的抗组胺,6mg的薄荷醇,10mg的硼砂,1800mg的硼酸,15mg的糖胺聚糖混合进100ml的蒸馏水中,通过常规方法制得的眼药水,经过试验得出,对于干眼症或者其他炎症的患者,不仅能取得优异的治疗效果,而且一点不刺激,使用过后不产生瘙痒的感觉,非常舒适清新。
在本发明另一实施方式中,还包括5~10mg的双氯芬酸的药学活性剂。少量加入后能够提升眼药水的表面活性,提升亲水亲油性。
此外,本发明还包括增粘剂和pH调节剂。
增粘剂选自甲基纤维素,羟乙基纤维素,羧甲基纤维素,羟丙基甲基纤维素,聚乙烯醇。提升溶液滴取后的粘性,防止溶液粘度不够,从眼眶流出。
pH调节剂选自氢氧化钠,氢氧化钾,碳酸钠,柠檬酸,磷酸,乙酸和盐酸。调节pH值,控制酸碱度,适应用户眼部。
最终制得的溶液的pH为7,适应大多数用户酸碱度的平衡,使用舒适。
上述说明示出并描述了本发明的若干优选实施例,但如前所述,应当理解本发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文所述发明构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离本发明的精神和范围,则都应在本发明所附权利要求的保护范围内。
Claims (8)
1.一种有效缓解干眼症的眼药水,其特征在于,100ml无菌蒸馏水中包括色甘酸钠1000mg,抗组胺15mg,薄荷醇6mg,硼砂10mg,硼酸1800mg,糖胺聚糖15mg。
2.根据权利要求1所述的有效缓解干眼症的眼药水,其特征在于,其中所述糖胺聚糖选自透明质酸。
3.根据权利要求1所述的有效缓解干眼症的眼药水,其特征在于,其中所述抗组胺选自马来酸氯苯那敏或盐酸苯海拉明。
4.根据权利要求1所述的有效缓解干眼症的眼药水,其特征在于,还包括5~10mg的双氯芬酸的药学活性剂。
5.根据权利要求1所述的有效缓解干眼症的眼药水,其特征在于,还包括增粘剂和pH调节剂。
6.根据权利要求5所述的有效缓解干眼症的眼药水,其特征在于,其中所述增粘剂选自甲基纤维素,羟乙基纤维素,羧甲基纤维素,羟丙基甲基纤维素,聚乙烯醇。
7.根据权利要求5所述的有效缓解干眼症的眼药水,其特征在于,其中所述pH调节剂选自氢氧化钠,氢氧化钾,碳酸钠,柠檬酸,磷酸,乙酸和盐酸。
8.根据权利要求5所述的有效缓解干眼症的眼药水,其特征在于,其中溶液的pH为7。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811034727.6A CN110876755A (zh) | 2018-09-06 | 2018-09-06 | 一种有效缓解干眼症的眼药水 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811034727.6A CN110876755A (zh) | 2018-09-06 | 2018-09-06 | 一种有效缓解干眼症的眼药水 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110876755A true CN110876755A (zh) | 2020-03-13 |
Family
ID=69728226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811034727.6A Withdrawn CN110876755A (zh) | 2018-09-06 | 2018-09-06 | 一种有效缓解干眼症的眼药水 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110876755A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022257981A1 (zh) * | 2021-06-08 | 2022-12-15 | 广州岐微生物医药科技有限公司 | 化合物在抑制或杀灭螨虫及治疗干眼症中的应用 |
-
2018
- 2018-09-06 CN CN201811034727.6A patent/CN110876755A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022257981A1 (zh) * | 2021-06-08 | 2022-12-15 | 广州岐微生物医药科技有限公司 | 化合物在抑制或杀灭螨虫及治疗干眼症中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
JP6014033B2 (ja) | 防腐剤無添加ビマトプロストおよびチモロール溶液 | |
WO2001041806A1 (fr) | Compositions ophtalmiques | |
JP2011503061A (ja) | 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物 | |
US11857537B2 (en) | Use of prostacyclin antagonists for treating ocular surface nociception | |
TW201206418A (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
US20120027842A1 (en) | Topical formulations of flap inhibitors for administration to an eye | |
US20220257593A1 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
JP2022508715A (ja) | 緑内障および関連状態の処置のための方法および組成物 | |
AU2011282679A1 (en) | Preservative free bimatoprost solutions | |
CN110876755A (zh) | 一种有效缓解干眼症的眼药水 | |
TW201815397A (zh) | 眼科用劑、眼科用藥、以及(a)羥丙基甲基纖維素及(b)維生素e類的用途 | |
Diestelhorst et al. | The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study | |
CN114832034A (zh) | 一种持久缓解干眼症的眼药水 | |
KR20230098630A (ko) | 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물 | |
Wagh et al. | Drug delivery and pharmacotherapy for dry eye disease | |
Chi et al. | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension | |
JP2024515714A (ja) | 散瞳、緑内障、及び他の眼の病態を治療するための方法及び組成物 | |
Jankauskienė et al. | Investigation of ocular changes in children and young people with thyroid diseases before and after the treatment with 20% honey solution eye drops |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200313 |
|
WW01 | Invention patent application withdrawn after publication |